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Hereditary Breast and Ovarian Cancer (HBOC) syndrome is due to mutations in
BRCA1 and BRCA2 genes. Women with HBOC have high risks to develop breast and
ovarian cancers. Males with HBOC are commonly overlooked because male breast cancer is
rare and other male cancer risks such as prostate and pancreatic cancers are relatively low.
BRCA genetic testing is indicated for men as it is currently estimated that 4-40% of male
breast cancers result from a BRCA1 or BRCA2 mutation (Ottini, 2010) and management
recommendations can be made based on genetic test results. Risk assessment models are
available to provide the individualized likelihood to have a BRCA mutation. Only one study
has been conducted to date to evaluate the accuracy of BRCAPro in males and was based on
a cohort of Italian males and utilized an older version of BRCAPro.
The objective of this study is to determine if BRCAPro5.1 is a valid risk assessment
model for males who present to MD Anderson Cancer Center for BRCA genetic testing.
BRCAPro has been previously validated for determining the probability of carrying a BRCA
mutation, however has not been further examined particularly in males.
The total cohort consisted of 152 males who had undergone BRCA genetic testing.
The cohort was stratified by indication for genetic counseling. Indications included having a
known familial BRCA mutation, having a personal diagnosis of a BRCA-related cancer, or
having a family history suggestive of HBOC. Overall there were 22 (14.47%) BRCA1+
males and 25 (16.45%) BRCA2+ males. Receiver operating characteristic curves were
constructed for the cohort overall, for each particular indication, as well as for each cancer
subtype. Our findings revealed that the BRCAPro5.1 model had perfect discriminating
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ability at a threshold of 56.2 for males with breast cancer, however only 2 (4.35%) of 46
were found to have BRCA2 mutations.
These results are significantly lower than the high approximation (40%) reported in
previous literature. BRCAPro does perform well in certain situations for men. Future
investigation of male breast cancer and men at risk for BRCA mutations is necessary to
provide a more accurate risk assessment.
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BACKGROUND
Introduction
Hereditary Breast and Ovarian Cancer (HBOC) is a hereditary cancer syndrome
caused by mutations in the BRCA1 and BRCA2 genes and is inherited in an autosomal
dominant manner. Since the discovery of BRCA1 and BRCA2 genes in 1994 and 1995,
respectively [1,2] there have been many research studies conducted on this topic. The
BRCA1 gene is located on chromosome 17q21, consists of 1,863 amino acids, and plays an
important role in DNA repair, cell-cycle-checkpoint control, protein ubiquitylation and
chromatin remodeling [3]. The BRCA2 gene is located on chromosome 13q12.3 and consists
of 3,418 amino acids. To date, the exact function of BRCA2 is not as well known, however
both BRCA1 and BRCA2 play important roles in DNA repair, more specifically in
homologous recombination [3]. Inheriting a BRCA1 or a BRCA2 mutation puts both males
and females at risk to develop certain types of cancers at earlier ages than the general
population.
Mutations in BRCA1 and BRCA2 confer the highest risk for women to develop breast
and ovarian cancers. Women who are found to be BRCA1 mutation carriers have up to an
85% lifetime risk of developing breast cancer and a 45% lifetime risk of developing ovarian
cancer [4]. For women who are BRCA2 mutation carriers, the lifetime risks to develop
breast and ovarian cancer are up to an 84% risk and an up to a 27% risk, respectively [5].
These numbers are increased well above the general population lifetime risks for a woman
to develop breast cancer and ovarian cancer. According to Surveillance, Epidemiology and
End Results (SEER) the general lifetime population risk for women to develop breast cancer
is 12.29% [6]. SEER data estimates that the general population lifetime risk for women to
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develop ovarian cancer is 1.40% [6]. The vast majority of information known about BRCA1
and BRCA2 is through research conducted on women with BRCA mutations.
BRCA1 and BRCA2 mutations are aolso associated with an increased risk for men to
develop male breast cancer and prostate cancer with a higher risk conferred by having a
BRCA2 mutation [7]. The general population lifetime risk for men to develop prostate
cancer is 16% [8]. The general population lifetime risk for men to develop breast cancer is
0.1% [9]. Both male and female BRCA2 mutation carriers are at an increased risk to develop
pancreatic cancers with up to a 7% lifetime risk seen for males and up to a 3% lifetime risk
seen for females [5].

Male Breast Cancer
Male breast cancer is extremely rare and only accounts for 1% of all breast cancers
[10]. In the United States, it is estimated that there are approximately 1,970 new cases of
male breast cancer diagnosed each year with 390 deaths resulting from male breast cancer
[10]. Male breast cancer usually first comes to attention due to one or more of the following
symptoms: painless subareolar lump, nipple retraction, or bleeding from the nipple [11]. In
comparison female breast cancers are commonly diagnosed through one of two methods,
which include screening measures such as breast mammograms, MRIs, and ultrasounds or
when the tumor has grown to a size that creates a lump that is palpable on physical exam
[12]. Less common signs and symptoms in female breast cancers include breast pain or
heaviness, swelling, thickening or redness of the skin covering the breast, nipple discharge,
and changes to the nipple such as erosion, inversion, or tenderness [12]. Screening
mammography starting at age 40 for women in the general population is universally

2

recommended [13]. The advances made in screening technology along with addition in
adjuvant advances can be attributed to the 2.2% per year decrease seen in breast cancer
mortality rates in the United States since 1990 [5].
Male breast cancers historically differ from female breast cancers in several different
aspects. Male breast cancers, when compared to female breast cancers, are diagnosed at
later ages and at more advanced clinical stages, with greater tumor sizes and more frequent
involvement of the lymph nodes [9]. In comparison to the mean age of diagnosis of breast
cancer in women of 62 years, male breast cancer is diagnosed five years later, with the mean
age of diagnosis for male breast cancer being 67 years [11]. A similarity seen between male
and female breast cancer is that there is a slight preponderance of left-sided disease over
right-sided disease [11].
Tumor marker status for male breast cancers differs when compared to female breast
cancers, as these markers are much more likely to be both estrogen and progesterone
receptor positive. More than 90% of male breast cancers are found to be estrogen receptor
positive, with the majority also being progesterone receptor positive at approximately 81%
[11,14]. Male breast cancers are most commonly found to be HER2 negative, with
estimation that only 10% of male breast cancer tumors demonstrate HER2 amplification
[15].
The Surveillance, Epidemiology, and End Results (SEER) registry collected data on
breast cancer from 1973 through 2005 and has a collection of 5,494 male breast cancer cases
[9]. The SEER data set found that in their male breast cancer cases, 11% were diagnosed
with ductal carcinoma in situ [9]. Most frequently, male breast cancer is confirmed by
pathology to be invasive ductal carcinoma [11]. In male breast cancer, the histology
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subtypes of lobular, mucinous, medullary and papillary account for only about 5% of cases
[11]. The risk to develop breast cancer increases at a steady linear rate in regard to age for
males with a peak being reached at approximately 75 years of age [9]. The linear rate
observed in male breast cancers is in contrast to the bimodal distribution, also known as
Clemmesen’s hook, seen in regard to age of diagnosis for females [9]. The incidence of
male breast cancer varies based on race, for example black males having a higher incidence
of 1.8 per 100,000 as compared to white males having an incidence of 1.1 per 100,000 [9].

Male Breast Cancer Risk Factors
There are many different factors that may increase a male’s risk to develop breast
cancer in his lifetime. In addition to mutations in BRCA1 and BRCA2, there are other
genetic factors that have been suggested as conferring an increased risk for male breast
cancer, more specifically mutations in PTEN, CHEK2 [9]. The risks for male breast cancer
associated with mutations in PTEN, CHEK2 are substantially lower than the risk for male
breast cancer with a BRCA1 or BRCA2 mutation. Klinfelter syndrome, a sex chromosome
disorder diagnosed with karyotype of XXY, has been described as occurring in 3% to 7.5%
of males with breast cancer [9,11]. Individuals with Klinefelter syndrome have been
suggested to have up to a 50 times higher risk to develop breast cancer in comparison to
males in the general population [16]. Determining the exact risk factor for male breast
cancer in regard to Klinefelter syndrome is complicated due to the relative rarity of these
two factors.
Gynecomastia is defined as the abnormal development of large mammary glands
resulting in breast enlargement in males [16]. It is thought that gynecomastia is a risk factor
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for the development of male breast cancer due to an increased amount of breast tissue.
Gynecomastia is the most common benign breast condition noted in males, occurring in
approximately 30% of healthy men [11,17]. Having at least one female relative diagnosed
with breast cancer increases a man’s likelihood to develop breast cancer 2.5 times [11]. In
summary, risk factors for the development of male breast cancer include genetic mutations,
hormonal and personal factors, family history of breast cancer, and environmental factors.
Both males and females who receive chest wall radiation for various indications such as
treatment for Hodgkin’s lymphoma are at increased risk to develop breast cancer [11].
Several risk factors have been proposed to exist with male breast cancer and include alcohol
use, liver disease, obesity, electromagnetic field radiation and diet; although further
investigation is needed at this point to prove associations [11].

Treatment for Male Breast Cancer
As previously stated, male breast cancer is rare; due to this fact there have only been
retrospective analyses performed in evaluating treatment options for male breast cancer at
this point in time. Treatment choices for male breast cancer are similar to the options
available for female breast cancer and include surgery, adjuvant therapy, radiation and
chemoprevention [18]. In regard to surgical options, males generally undergo a modified
radical mastectomy due to the relatively small amount of male breast tissue along with the
fact that most male breast tumors are centrally located [19]. Male breast cancer patients are
more likely than their female counterparts to receive radiation due to the presence of
advanced disease [20]. Since the vast majority of male breast cancers are estrogen and
progesterone positive tumors, the chemoprevention agent Tamoxifen has recently been
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studied in this patient population based on data established in female breast cancers that this
agent improves survival along with decreasing recurrences of breast cancer [18]. There are
concerns that need to be considered when prescribing hormonal agents like Tamoxifen to
male patients, such as potential undesirable side effects, which may cause males to
discontinue this treatment [21]. Pemmaraju et al. (2011) recently carried out a retrospective
review of 64 male breast cancer patients who were treated with Tamoxifen and found that
20.3% of patients altogether discontinued Tamoxifen citing specific side effects. In addition
to clinicians continuing to increase patient awareness of unpleasant side effects, more
research is needed focused on evaluating the use of Tamoxifen in males.

Prostate Cancer
Prostate cancer is currently the most commonly diagnosed male cancer in North
America [22]. It is estimated that in 2011, 240,000 men will be diagnosed with prostate
cancer and result in 34,000 deaths [8]. It has been established that BRCA2 carriers have
between a 2-5 relative risk for prostate cancer, whereas BRCA1 carriers have between a 1-3
relative risk [21]. The NCCN guidelines recommend that both the risks and benefits of
screening for prostate cancer be discussed with male BRCA carriers at age 40. The
American Cancer Society recommends that men at high risk for developing prostate cancer
should begin having specific antigen tests (PSA) and digital rectal examinations (DRE) at
age 40. The American Cancer Society defines high risk as males who have multiple
relatives with prostate cancer, which is an important distinction to make since this definition
does not specifically include BRCA carriers. However, the utility of prostate screening is
currently a subject of contention and disagreement among many medical professionals. It
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will be imperative in the coming years for both male BRCA carriers as well as men in the
general population to stay abreast on research regarding this topic.

Prostate Cancer Risk Factors and Treatment
There are numerous risk factors that are known to increase the risk for prostate
cancer in males. Increasing age, positive family history, and being of African American
heritage are the risk factors that are have been found to be most strongly associated with
prostate cancer [23]. “The median age of diagnosis of prostate cancer is 67 years and the
median age of death is 81 years” [22]. Men who have at a first degree relative diagnosed
with prostate cancer are at a two-fold increased risk to develop prostate cancer in
compassion to their counterparts with no apparent family history [24]. For reasons not well
understood at this point in time, African American males have a higher incidence of prostate
cancer and are also more likely to receive the diagnosis at an advanced stage of disease
when compared to Caucasian and Hispanic males [23].
Once a prostate cancer is detected there are numerous different approaches to
managing the disease, often times decisions are based on several different factors such as the
patient’s age, if the cancer has spread, other medical conditions, along with the patient’s
overall health [25]. There are several different treatment options when the prostate cancer
has not metastasized and include watchful waiting, radical prostatectomy, radiation therapy
either internal or external, hormone therapy, and crypotherapy [25].
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Pancreatic Cancer
Of all cancers diagnosed in the United States, pancreatic cancers are the fourth
deadliest [26]. Although rare in occurrence, representing only 3% of cancers each year,
pancreatic cancer accounts for 6% of all cancer related deaths [10] (Jemal et al, 2007). It is
estimated that 10% of pancreatic cancers are due to heritable genetic mutations and/or
familial patterning of inheritance [27,28]. BRCA mutation carriers are at increased risk to
develop pancreatic cancer, with BRCA2 carriers having around a 5% lifetime risk to develop
pancreatic cancer [5]. It is estimated that BRCA1 mutation carriers have approximately a
2.26 increased risk to develop pancreatic cancer in comparison to the general population
[29]. In the Ashkenazi Jewish population, there is a particular BRCA2 mutation, 6174delT,
that has been found in families who have higher incidences of pancreatic cancer [26]. In the
Asheknazi Jewish population BRCA2 mutations have been found to be associated with 10%
of unselected, apparently sporadic pancreatic cancers [30]. Unfortunately at this point in
time there are not reliable methods for screening and early detection of pancreatic cancers,
even though individuals at increased risk based on gene mutations or family history could
benefit from such screening. Detecting small pancreatic cancers along with premalignant
lesions of the pancreas is complicated by the fact that neither lesion shows symptoms [26] .
If an individual is identified as being at an increased risk for the development of pancreatic
cancer, there are several available ongoing clinical trials looking to identify the most reliable
screening method for this patient population.
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Pancreatic Cancer Risk Factors and Treatment
Pancreatic cancer is considered to be multifactoral in its development. Risk factors
include smoking, family history of chronic pancreatitis, advancing age, male sex, diabetes
mellitus, obesity, non-O blood type, occupational exposures such as nickel, and diet [31].
Possible risk factors for pancreatic cancer may include Helicobacter pylori infection and
periodontal disease [29]. Another genetic risk factor for developing pancreatic cancer is
seen in individuals with hereditary pancreatitis, which is a rare inherited form of chronic
pancreatitis caused by germline PRSS1 mutations [32]. Notably a positive history of
cigarette smoking and/or use of other tobacco products is present in 20% of all patients with
pancreatic tumors [33].
For pancreatic cancer patients, the only potentially curative treatment is a
pancreatectomy, for which only 15-20% of patients will qualify for this course of treatment
[32]. In comparison to patients with unresectable pancreatic tumors, patients who undergo a
pancreatectomy have a higher 5-year survival rate, although it is still relatively low with the
5 year survival rate being 25-30% in node-negative patients and 10% in node-positive
patients [30].

BRCA Testing in males who present with BRCA associated cancers
BRCA genetic testing is indicated in this patient population as it is currently
estimated that up to 40% of male breast cancers result from a BRCA2 mutation whereas up
to 4% of cases are estimated to result from a BRCA1 mutation [7,14,34]. Males who are
known BRCA1 mutation carriers are quoted as having a 5.8% lifetime risk to develop breast
cancer, whereas males with a known BRCA2 mutation have a 6.9% lifetime risk to develop
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breast cancer, which is 80-100 times increased above the general population risk [7]. The
general population lifetime risk to develop breast cancer for males is 0.1% [9]. Mutations in
both BRCA genes also confer an increased risk for males to develop prostate and pancreatic
cancers [7]. In regard to BRCA mutations it is more common for males with breast cancer to
be BRCA2 mutation carriers. Although one study found that more than one-third of the
BRCA mutations that were identified in their cohort of 76 men with breast cancer were
BRCA1 [35]. A predisposition to develop other cancers such as melanoma and stomach
cancer may also exist due to BRCA1 and BRCA2 mutations [22].

Screening Recommendations
The National Comprehensive Cancer Network has put forth screening guidelines
for men who are found to be BRCA1 or BRCA2 mutation carriers. The NCCN is
comprised of 21 cancer centers and is considered to be a leading authority providing expert
opinions in the field of cancer. The NCCN 2011guidelines for male BRCA1 and BRCA2
mutation carriers include:
“breast self-exam training and education starting at age 35, clinical breast exam ,
every 6-12 months, starting at age 35 years, consider baseline mammogram at age
40; annual mammogram if gynecomastia or parenchymal/glandular breast density on
baseline study, as well as adhere to screening guidelines for prostate cancer.” [36]
In males undergoing mammography, the sensitivity is reported to be 92% with 90%
specificity in the diagnosis of male breast cancers [11,37]. Because of their increased
lifetime cancer risks, it is important to identify males with BRCA1 and BRCA2 mutations
early so that screening can be implemented in the hopes of preventing cancer altogether.
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Clinical BRCA Testing
Myriad Genetic Laboratories first made testing for BRCA1 and BRCA2 mutations
available in 1996 [38]. Currently, genetic counselors and other health care providers utilize
statistical models along with clinical judgment to determine if individuals are candidates for
BRCA genetic testing. Indications for BRCA genetic testing include a personal history of
early onset breast and/or ovarian cancer and positive family history the family history
features that are suggestive of a hereditary form of breast and ovarian cancer include: close
relatives with breast, ovarian or other related cancers, premenopausal breast cancer
diagnoses, multiple related cancers in an individual, male breast cancer, similar cancers in
multiple generations, and Ashkenazi Jewish ancestry. The NCCN recommends offering
BRCA testing to any male diagnosed with breast cancer in order to investigate the possibility
of a genetic cause; therefore it is routine practice in the clinical setting [36] [39].
When considering BRCA genetic testing, it is important to understand the different
types of tests that are currently available. If an individual reports being of Ashkenazi Jewish
ancestry, it is most appropriate to begin testing with the Ashkenazi Jewish Multisite 3
BRACAnalysis® test. This is due to the fact that the majority of mutations in Ashkenazi
Jewish individuals occur in one of three common founder mutations two in BRCA1
(187delAG, 5385insC) and one in BRCA2 (6174delT) [35]. If there is a known BRCA
mutation within a family, testing should first be ordered for that particular known familial
mutation, however if this individual is found to have an Ashkenazi Jewish founder mutation
then the multi-site panel should be ordered for their family members. In both of these cases,
if a negative test result is obtained, there is always the option to additional BRCA testing.
Therefore, one patient could have multiple types of BRCA testing ordered. Comprehensive
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BRCA genetic testing should be the first line of testing ordered for individuals without a
known familial mutation or any report of Ashkenazi Jewish ancestry. Comprehensive
testing involves sequencing both BRCA1 and BRCA2. BRACAnalysis Large Rearrangement
Test (BART) is testing offered through Myriad clinically as of August 2006 and involves
testing for large rearrangements, deletions or duplications that are otherwise missed by
sequencing. The yield for mutations found by BART is relatively low, although varies based
on ethnic groups.
After BRCA testing is ordered there are three possible test results that a patient can
receive. The first test result is that of a positive result, meaning a mutation was detected.
Individuals with a positive test result should follow screening recommendations such as
those outlined by the NCCN and encourage other family members to seek genetic
counseling and be tested for the mutation that was identified. A negative test result means
that no mutation was identified based on the testing ordered. Individuals who receive this
result should be considered for additional reflex testing if either their personal and/or family
history is highly suggestive of HBOC. Lastly, there is the result of a variant of uncertain
significance meaning that a sequence change was identified, however it is unclear whether
that specific change is deleterious or a polymorphism.

Risk Assessment Models for Genetic Mutations
Certain cancer genetic risk assessment models are used by clinicians to give their
patients an individualized risk to develop a particular cancer or the chance to have a BRCA
mutation, which in turn can assist patients in making informed decisions about undergoing
genetic testing. Three men from Duke University Institute for Statistics and Decision
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Sciences created BRCAPro [40]. BRCAPro has been validated as an accurate counseling
tool for determining the probability of carrying BRCA1 and BRCA2 mutations [41].
BRCAPro utilizes personal history and family history of first and second-degree relatives’
diagnoses of cancer in addition to other characteristics such as hormone receptor status
(breast cancer), oophorectomy, ethnicity, and Ashkenazi Jewish ancestry to provide an
accurate risk assessment. BRCAPro is a risk assessment model based on Baye’s theorem,
which takes into account both affected and unaffected individuals to calculate an
individual’s conditional probability to have a mutation in either BRCA1 or BRCA2. In the
case of BRCAPro, the condition is having a personal history of cancer, family history of
cancer, or both. The question generated by BRCAPro is “given this pattern of affected and
unaffected relatives, what is the probability that this individual carries a mutation in one of
the BRCA genes?” [40]. CancerGene Version 5.1 is available as a free online download,
and includes BRCAPro (UT Southwestern Medical Center of Dallas © 1998-2010).
BRCAPro version 5.1 has been updated to include race-specific calculations and uses
Myriad BRCA prevalence tables from February 2010.
The overall accuracy of this model is dependent on both the frequency and
penetrance of BRCA mutations in the specific population of interest [42]. An initial
limitation of BRCAPro as a risk assessment model is that it was developed and thus first
validated in individuals, mainly women, of Ashkenazi Jewish or European descent and
therefore may not be as meaningful or useful in minority populations [42]. Minority
populations represent less than 10% of individuals who uptake BRCA genetic testing,
according to data from Myriad Genetic Laboratories [42]. The small number of minorities
who have undergone BRCA genetic testing only further complicates the issue of validating
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BRCAPro in these populations. However, one study conducted in 2009 studied a total of
292 minority families which included African Americans, Hispanics, Asian-Americans,
Native Americans as well as a few other less represented minorities in the United States,
who had at least one family member who had undergone BRCA mutational testing in order
to access BRCAPro’s ability to accurately detect mutation carriers. This study found that
BRCAPro performed the most reliably in Hispanics with the highest AUC of 0.83, and the
least reliably in African Americans with an AUC of 0.68 [42]. Similar to the small number
of studies that have focused on validating BRCAPro use in minority populations, relatively
no studies have focused on the utilization of this model in males.
Zanna et al, (2010) found in their study of 102 Italian men with breast cancer, that
BRCAPro had the highest combination of sensitivity, specificity, negative predictive value,
and positive predictive value out of four different risk assessment models [34]. However,
further research is needed for the male breast cancer population and males in general
undergoing BRCA genetic testing.
One recent study found the BRCAPro model was overestimating the relative
contribution that female bilateral breast cancer had on the likelihood of detecting either a
BRCA1 or BRCA2 mutation in their cohort of 66 women with a personal history of bilateral
breast cancer [43]. Further investigation into male breast cancer may produce findings
similar to Ready et al, (2009) in regard to BRCAPro overestimating their likelihood to be
BRCA mutation carriers.
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Objective
The objective of this study was to determine if BRCAPro is a valid risk assessment
model to use for all males who present for BRCA genetic testing. Findings from this study
will help clinicians offering testing to male breast cancer patients or who have a significant
family history that is suggestive of HBOC to determine the most appropriate testing
candidates and accurately assess their risk to test positive. Additionally, this study may
facilitate the development of a new risk assessment model specifically for males, if the
BRCAPro model is not validated in this study population.
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METHODS AND MATERIALS
This study was a retrospective chart review of all males who have presented to MD
Anderson Cancer Center for genetic counseling in the high-risk genetics clinics and had
BRCA testing performed. A chart review through MD Anderson Cancer Center’s electonric
medical record (EMR) was performed to obtain relevant information for study participants.
The specific aim of this study was to determine if BRCAPro version 5.1 is a valid risk
assessment tool in affected males who have undergone BRCA genetic testing. Males who
had undergone predictive testing, or those with a known familial mutation (KFM) were
included in this study, however were analyzed separately from males affected with a BRCA
related cancer that presented as the index case in their family for BRCA testing. We
hypothesized that BRCAPro5.1 will overestimate the likelihood for a male to have either a
BRCA1 or BRCA2 mutation.

Study Approval
The University of Texas-Houston Health Science Center’s Intuitional Review Board
approved this study on July 25th, 2011. The Committee for the Protection of Human Subjects
of MD Anderson approved this study on November 3rd, 2011.

Study Population
The study population consisted of 152 MD Anderson Cancer Center male patients
who underwent BRCA testing through Myriad Genetics Laboratory in Salt Lake City, Utah.
However, one study participant had BRCA testing performed through Oxford Radcliffe
Hospitals Genetics Laboratories in Oxford, OX.
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Ascertainment
An IRB approved research database at MD Anderson Cancer Center was used to
identify potential study participants. The study population included patients seen at MD
Anderson between February 1997 to September 2011. An initial query revealed 215 males
had presented to MD Anderson for BRCA testing, however 54 of these patients were
excluded based on the fact that they were missing medical record numbers. A total of 161
patients were identified as potential study participants and their fulfillment of the inclusion
criteria was confirmed during review of their medical records. Of the 161 patients, in total
nine were excluded because they did not meet the inclusion criteria of the study. The
following individuals were excluded from our data: women, individuals who did not have
electronic medical records on file, individuals who did not have a genetic counseling note as
reliable family history could not be obtained, males with a variant of uncertain significance
and no deleterious mutation, males who were identified to have another hereditary cancer
syndrome aside from HBOC and males whose BRCA testing was never performed. Males
who were noted to have a variant of uncertain significance in either BRCA1 or BRCA2 that
were classified as suspected deleterious were included due to the fact that these individuals
are treated from a clinical standpoint as having a mutation. Males who were noted to have a
variant of uncertain significance in either BRCA1 or BRCA2 classified as a favored
polymorphism were included and treated as a negative result. Males who were diagnosed
with ductal carcinoma in situ (DCIS) were included in the cohort and entered into BRCAPro
has having DCIS at their age of diagnosis as opposed to entering their DCIS as invasive
breast cancer developing 10 years after the DCIS.
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Figure 1: Flowchart of final study population

BRCAPro Risk Calculation
All study participants had their individual BRCAPro numbers calculated by entering
both their personal and family history into the BRCAPro 5.1 model, which generates both a
pedigree and risk calculation. Study participants’ ethnicities were recorded by self-report at
their genetic counseling appointment. Males who were diagnosed with ductal carcinoma in
situ (DCIS) were included in the cohort and entered into BRCAPro has having DCIS at their
age of diagnosis as opposed to entering their DCIS as invasive breast cancer developing 10
years after the DCIS. Males who were undergoing predictive testing had their KFM entered
into the program to most accurately predict their own likelihood to test positive.
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Data Collection
The study population’s medical records at MD Anderson Cancer Center were
reviewed December 2011 through March 2012. The information extracted from the medical
records is displayed in table 1.

Table 1 Information Obtained from Chart Review through MD Anderson EMR
Demographic and General Information
Indication for genetic counseling
Date of birth
Ethnicity including Ashkenazi Jewish
Age of diagnosis of all cancer diagnoses
Height and weight (at initial appointment) to calculate BMI
Gynecomastia if noted on psychical exam (at initial appointment)
Tumor Information
Receptor status of breast tumor
Pathology of tumor
History of previous biopsy
Treatment options
Family History
First and second degree relatives (sometimes third degree) with reported cancer
diagnoses
Gender of family members
Ages of diagnoses of these cancers if reported
Ages of deaths of these individuals if reported
Pedigrees constructed from the genetic counseling appointment
Testing Information
Type of testing ordered
Date of testing
Testing result
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Statistical Analysis
Numerous computer programs were utilized to analyze this data set. Access 2010
was used to create a secure password protected database for all information collected from
the chart review portion. Microsoft Excel 2010 was used as a means of organizing the data.
STATA 10.0 was used to perform descriptive statistics.
We constructed receiver operating characteristic (ROC) curves to evaluate the
discriminatory value of the BRCAPro5.1 model. ROC curves are constructed by plotting
the sensitivity on the y axis against 1-specificity on the x axis. When discussing the
likelihood of having a BRCA mutation, sensitivity and specificity have equal importance
since it can be argued harm could be afflicted for calling either false positives or false
negatives. Therefore, in order to set our threshold value for our ROC curve, the Youden’s
index (J) was calculated, since it was determined that both sensitivity and specificity are
equally critical. The maximum theoretical value for J is 1, in the case of a test having
perfect discriminatory value or the ability to accurately determine individuals who will test
positive from those who will test negative.
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RESULTS
In total 152 male patients were included in our cohort; 57% (87/152) presented for
BRCA testing due to a personal history that was suggestive of a BRCA mutation as defined
as having a personal diagnosis of male breast cancer, pancreatic cancer and/or prostate
cancer, 36% of our patients were seen for predictive testing with a KFM and 7% presented
to clinic due to a family history that was suggestive of a BRCA mutation (Figure 1). Table 1
summarizes the number of study participants seen for each indication with 54 males
presenting to clinic with a KFM, 87 males presenting to clinic due to a personal history
suggestive of a BRCA mutation (diagnosis of male breast cancer, prostate, pancreas) and 11
males presenting to clinic due to a family history suggestive of a BRCA mutation. A family
history suggestive of a BRCA mutation included males of Ashkenazi Jewish ancestry, first
and/or second degree relatives with early age of onset and higher than expected diagnoses of
BRCA related cancers in family members (breast, ovarian, prostate, pancreatic). Therefore,
the majority of our study cohort was seen due to a personal cancer history that was
suggestive of a BRCA mutation. Results from our study were stratified based on the
indication for having BRCA testing, as these groups were analyzed separately from one
another.
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Figure 2: Indication for BRCA Testing

Indication
7%

57%

36%

Known Familial Mutation
Personal History Suggestive of a BRCA
Mutation
Family History Suggestive of a BRCA
Mutation

N=152

Demographics
The vast majority of our study population was Caucasian with a total of 94 males
(61.84%). This number increases to 129 males (84.87% ) if you add in the ethnic group who
reported themselves as Ashkenazi Jewish which is a subset of Caucasian. The ethnicity of
our cohort is summarized in Table 2.
The overall mean age of the study cohort at the time they presented for BRCA testing
was found to be 57.43 with a standard deviation of 14.59 and a range from 19 to 88 years.
When looking at the dataset stratified by indication, it was noted that the lowest mean age
was 51.06 with a standard deviation of 17.81 and a range from 19 to 79 years for individuals
who were undergoing predictive testing. The highest mean age of 61.31 with a standard was
seen for individuals who had a personal cancer diagnosis suggestive of a BRCA mutation.
The findings for the age of our study population are summarized in Table 2.
When looking at the vital status of our study cohort, it was seen that overall the
majority of participants were still living (80.26%; n=122) when our chart review was
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performed, while 30 males were deceased representing 19.74% of the cohort. The majority
of deceased males had a personal history of cancer, (93.3%, n=28). The vital status of the
study participants from the time of the chart review are summarized in Table 2.

Table 2: Demographic Information of Study Cohort

Variable

Known
Familial
Mutation

Personal
History

Family
History

Overall

N

54 (35.53%)

87 (57.24%)

11 (7.24%)

152

Age (Mean, SD)

51.06
(17.81)
38 (70.37%)

61.31
(11.36)
52 (59.77%)

58.36
(8.26)
4 (36.36%)

57.43
(14.59)
94 (61.84%)

Ashkenazi 8 (14.82%)
Hispanic
8 (14.82%)
Black
0
Asian
0
Other
0
Alive
51 (41.80%)

20 (22.99%)
6 (6.90%)
4 (4.60%)
4 (4.60%)
1 (1.15%)
63 (51.64%)

7 (63.64%)
0
0
0
0
8 (6.56%)

35 (23.03%)
14 (9.21%)
4 (2.63%)
4 (2.63%)
1 (0.66%)
122 (80.26%)

Deceased

28 (93.33%)

0 (0.00%)

30 (19.74%)

Ethnicity Caucasian

Vital
Status

2 (6.67%)

Of our total cohort, 46 (30.26%) males were noted to have invasive breast cancer or DCIS.
The majority of males with breast cancer, 44, had an indication of having a personal diagnosis of
cancer, whereas the other 2 breast cancers were diagnosed in males who had a KFM. The overall
mean age of diagnosis for breast cancer not subdivided by indication was 60.13 with a standard
deviation of 10.83 and a range from 24 years to 87 years. The most common pathology was ductal
accounting for 38 (82.61%) of all the breast cancers diagnosed. The least common breast pathology
was mixed lobular and ductal as it was found in only 1 study participant (2.17%). The majority of
breast cancers diagnosed were both ER+ and PR+ with 40 breast cancers being ER+ and 38 breast
cancers being PR+, which represented 86.96% and 82.61% respectively of all the breast cancers
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diagnosed. The findings of breast cancers diagnosed, breast cancer subtype and tumor maker status
are summarized in Table 3.

Table 3: Breast Cancer Information and Subtype by Indication
Variable
Known
Personal
Family
Familial
History
History
Mutation
(n=87)
(n=11)
(n=54)
Breast Cancer Present

2 (3.70%)

44 (50.57%)

0

46 (30.26%)

62.50 (3.54)

60.02 (11.06)

0

60.13 (10.83)

2 (100%)

36 (81.82%)

0

38 (82.61%)

0

5 (11.36%)

0

5 (10.87%)

Papillary

0

2 (4.55%)

0

2 (4.35%)

Ductal and
Lobular

0

1 (2.27%)

0

1 (2.17%)

ER+

2 (100%)

38 (86.36%)

0

40 (86.96%)

PR+

2 (100%)

36 (81.82%)

0

38 (82.61%)

Her2neu+

1 (50%)

3 (6.82%)

0

4 (8.70%)

Age of Diagnosis
(Mean, SD)
Breast
Ductal
Cancer
Pathology
DCIS

Tumor
Markers

Overall
(n=152)

In addition to breast cancer, males in our study were noted to have several other
BRCA associated cancers. Across all three indications, prostate cancer was diagnosed in 21
males, which represented 13.82% of the entire study population. Overall the mean age of
diagnosis of prostate cancer was 57.47 with a standard deviation of 6.33 and a range from
47-70. Of the 21 prostate cases diagnosed, 16 cases were diagnosed in males seen due to
their cancer diagnosis while 5 cases of prostate cancers were diagnosed in males seen due to
having a KFM. Across all three indications, pancreatic cancer was diagnosed in 39 patients

24

(25.66%). Pancreatic cancer had a mean age of diagnosis of 56.16 years with a standard
deviation of 10.64 and a range from 34 to 80 years. Additionally, other cancer diagnoses
were also collected from the medical records. Overall the mean age of diagnosis of other
cancers was 58.60 with a standard deviation of 13.26 and a range from 33 to 80 years. Of the
54 males seen for an indication of a KFM, 10 (18.52%) were noted to have other cancers
that are not currently known to be associated with BRCA mutations and included: bladder
cancer, squamous cell carcinoma of the tongue, appendix cancer, colon cancer, basal cell
carcinoma, and duodenum. Of the 87 males seen for a personal cancer diagnosis suggestive
of a BRCA mutation, 21 (24.14%) were noted to have other additional cancer diagnoses
which included: basal cell carcinoma, pituitary cancer, bladder cancer, duodenal cancer,
colon cancer, clear cell carcinoma, thyroid cancer, lung cancer, squamous cell carcinoma,
esophageal cancer, and Non-Hodgkin’s lymphoma. Of the 11 males seen for a family history
suggestive of a BRCA mutation, 4 (9.09%) were noted to have a cancer diagnosis and
included: adenocarcinoma of unknown primary, lymphoma, anal cancer, and duodenal
cancer. The findings of other cancers, aside from breast cancer, diagnosed in our study
cohort can be found in Table 4.
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Table 4: Other Cancer Diagnoses by Indication
Other Cancers
Known
Personal
Familial
History
Mutation
(n=87)
(n=54)
Prostate Cancer
5 (9.26%)
16 (18.39%)

Family
History
(n=11)

Overall
(n=152)

0

21 (13.82%)

Age of Diagnosis
(Mean, SD)

53.6 (4.56)

58.69 (6.43)

0

57.47 (6.33)

Pancreatic Cancer

4 (7.41%)

35 (40.23%)

0

39 (25.66%)

Age of Diagnosis
(Mean, SD)

45.33 (3.06)

57.09 (10.56)

0

56.16 (10.64)

Other Cancers

10 (18.52%)

21 (24.14%)

4 (9.09%)

35 (23.03%)

Age of Diagnosis
(Mean, SD)

57.00 (14.70)

62.61 (9.49)

59.25 (10.18)

58.60 (13.26)

Several variables were looked at within our study to observe if there were particular
trends or associations in regard to male breast cancer. These variables included
gynecomastia, a history of a previous biopsy, radiation exposure, and if study participants
chose to have a prophylactic mastectomy of their unaffected breast after receiving their
breast cancer diagnosis. Overall the numbers were very low for these miscellaneous
findings and are summarized in Table 5.
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Table 5: Miscellaneous Information for Study Cohort by Indication
Miscellaneous
Known
Personal
Family
Findings
Familial
History
History
Mutation
(n=87)
(n=11)
(n=54)
Gynecomastia
1 (1.85%)
2 (2.30%)
0

3 (1.97%)

Previous biopsy

0

2 (2.30%)

0

2 (1.32%)

Radiation exposure

0

7 (8.05%)

1 (9.10%)

8 (5.26%)

Prophylactic
mastectomy

0

2 (2.30%)

0

2 (1.32%)

Overall
(n=152)

Table 6 summarizes the number of first and second degree relatives diagnosed with
particular cancers per family of our study participants. Cancers included in this table are
those known to be associated with BRCA mutations and included: breast cancer, male breast
cancer, ovarian cancer, breast and ovarian cancer in the same individual, prostate and
pancreatic cancer. Other cancers diagnosed in first and second degree relatives that are not
known to be associated with BRCA mutations were collected from the electronic medical
record and stored in our database; however, were not reported in this table. The family
history data is subdivided by the three indications males for seen for genetic counseling.
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Table 6: Family History (First and Second Degree Relatives) Information Per Family
Variable

Known Familial
Mutation
(n=54)

Personal History
(n=87)

Family
History
(n=11)

Total number
Mean (SD)

Total number
Mean (SD)

Total number
Mean (SD)

Individuals with breast cancer

70
2.55 (1.28)

75
0.86 (0.95)

20
1 (1.83)

Individuals with male breast
cancer

2
0.037 (0.19)

0

2
0.18 (0.40)

Individuals with ovarian
cancer
Individuals with prostate
cancer
Individuals with pancreatic
cancer
Individuals with breast and
ovarian cancer

28
0.52 (0.72)
5
0.09 (0.29)
8
0.15 (0.45)
8
0.15 (0.41)

10
0.11 (0.35)
34
0.39 (0.75)
7
0.51 (0.31)
0

1
0.17 (0.30)
1
0.17 (0.30)
5
0.45 (1.2)
0

Family History
(Per Family)

Of the 152 males in our study, 84 had a height recorded at the time of their initial
visit to MD Anderson (Figure 3). Therefore 68 males were missing a measurement for
height from their patient history database. It is seen that the height is normally distributed.
The mean for height in cm was 176.42 with a standard deviation of 6.54. The range of
values recorded for height in cm was 164 to 191. The p-value obtained from the skewness
test was 0.289.
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Figure 3: Height (cm) of Study Participants
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Of the 152 males in our study, 87 had a weight recorded at the time of their initial
visit to MD Anderson (Figure 3). Therefore 65 males were missing a measurement for
weight from their patient history database. It is seen that weight is not normally distributed
within our cohort. By looking at the graph it is seen to be skewed to the left, as several males
were noted to be overweight. The median for weight in kg was 87 with the IQR being from
77 at the 25th percentile to 97 at the 75th percentile. The p-value obtained from the
skewness test was <0.001.
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Figure 4:Weight (kg) of Study Participants
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Figure 4 shows the calculated body mass index, or BMI, of study participants
calculated for the 84 males who had both a recorded height and weight. BMI measurement
takes into account an individual’s height and weight and is calculated by the following
formula: weight (kg) / [height (m)]2. It is seen that BMI is not normally distributed within
our cohort as it is skewed to the right. The median BMI is 27.75 with an IQR of 25.20 to
30.98. The p value from the skewness test was 0.001.
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Figure 5: BMI for Males with Recorded Height and Weight
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BRCA Testing
Figure 6 displays the type of testing ordered across all three indications. For each
study participant it is important to understand that more than one test may have been
ordered. In total our cohort of 152 male, 174 BRCA tests were ordered. The most
commonly ordered tested was comprehensive testing, which accounted for 47% or 81 of the
total 174 tests ordered. It is seen that the least ordered test for our cohort was BART, as it
accounted for only 8% of all of the tests ordered.
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Figure 6: Type of BRCA Testing Ordered
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Figure 7 displays the overall BRCA test results of our cohort of 152 males. The
majority of males were found to be negative 104 (68.42%). In total 25 males (16.45%) were
found to be BRCA2 positive and 22 males (14.47%) were found to be BRCA1 positive, with
one male (0.65%) being found to have both a BRCA1 and BRCA2 mutation.

Figure 7: Overall BRCA Test Results
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The BRCA test results subdivided by indication are shown in a graph in figure 8.
The majority of individuals who were found to be BRCA1 positive (17) presented to clinic
for a KFM, which accounted for 77.28% of all of the males who were BRCA1 positive.
Similarly 17 males were found to be BRCA2+ who presented to clinic for a KFM, which
accounted for 68% of all BRCA2+ males. The majority of males tested due to a personal
history suggestive of a BRCA mutation (77) were found to be negative, which represented
74.04% of all BRCA negative males. One study participant presented to clinic for a KFM
and was found to have both a BRCA1 and BRCA2 which represented 0.65% of the total
cohort.

Figure 8: BRCA Test Results Stratified by Indication
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Table 7 summarizes both the type of BRCA testing ordered as well as the result of
the testing ordered for each specific indication. For each study participant it is important to
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understand that more than one test may have been ordered. The majority of study
participants who were seen for a KFM had single site testing performed, (n=42, 77.78%).
The second most commonly ordered test for males seen for this indication was the multisite
panel (n=12), which would be ordered for anyone whose familial mutation was one of the
three Ashkenazi Jewish founder mutations. The majority of individuals 74 (85.06%) seen for
genetic counseling due to a personal cancer history suggestive of BRCA had comprehensive
testing ordered. Similarly the majority of males, 6 (54.55%) who were seen due to a family
history suggestive of a BRCA mutation had comprehensive testing performed.

Table 7: BRCA Testing Ordered by Indication with Testing Results
Personal
BRCA Testing
Known Familial
History
Mutation
(n=87)
(n=54)
Single site (n)
42 (77.78%)
0
BRCA1+
13 (30.95%)
BRCA2+
14 (33.33%)
BRCA1+ & BRCA2+
1 (1.85%)
Negative
14 (33.33%)
Multisite/
12 (22.22%)
20 (22.99%)
Ashkenazi Panel (n)
BRCA1 +
4 (33.33%)
1 (%)
BRCA2+
3 (25.00%)
1 (%)
Negative
5 (41.67%)
18 (%)
Comprehensive (n)
2 (3.70%)
73 (83.91%)
BRCA1+
0
1 (1.39%)
BRCA2+
0
7 (9.59%)
Negative
2 (100%)
65 (89.02%)
BART (n)
BRCA1+
BRCA2+
Negative

1 (1.85%)
0
0
1 (100%)

11 (12.64%)
0
0
11 (100%)

Family
History
(n=11)
0

5 (45.45%)
1 (20.00%)
0
4 (66.67%)
6 (54.55%)
2 (40.00%)
0
4 (60.00%)
2 (18.18%)
0
0
2 (100%)

Figure 9 displays the number of BRCA tests ordered per patient. The majority of our
cohort, (86.84%, n=132) had one test ordered. A much smaller number, 18 males (11.84%),

34

had two tests ordered after receiving negative tests results from the first test ordered. The
most BRCA tests ordered for any one individual in our cohort was 3. In the case that a male
started with either single site or multisite testing then reflexed to comprehensive and then
additionally reflexed to BART testing. There were only 2 males (1.32%) that had 3 BRCA
tests ordered.

Figure 9: Overall Number of BRCA Tests Ordered per Patient
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BART testing has been clinically offered by Myriad as additional reflex testing for
negative test results since August 2006. In our study cohort, 25 males were tested before
BART testing was created which accounts of 16.45% of our total study cohort. Out of these
25 males, 9 had positive test results and 16 had negative test results. Therefore 16 males
were not offered BART testing as it did not yet exist. Of the 127 males who were tested
after August 2006, there were 39 males found to be positive and 79 were found to be
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negative test results. Of the males who were negative, only 14 decided to proceed with
BART testing and all 14 received negative test results. The results of males offered BART
within our cohort as well as how many BART tests were ordered are summarized in figure
10.

Figure 10: Flowchart of BART Tests Offered and Ordered

BRCAPro Scores
Table 8 summarizes the median calculated BRCAPro scores by the three different
indications. The median and IQR values are reported since the BRCAPro scores were found
to be skewed with a p-value <0.00005. The column denoted as “Overall” represents the
entire cohort, not subdivided by indication, and has a median of 3.85 with an IQR from 0.3
to 47.8. The indication with the highest median BRCAPro score of 49.4 was the known
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familial mutation subgroup. The indication with the lowest median BRCAPro score of 0.6
was a personal history of a BRCA associated cancer diagnosis.

Table 8: BRCAPro Calculated Scores by Indication
BRCAPro
Score

Median
IQR
Range

Known
Familial
Mutation
(n=54)
49.4
39.5 - 50.0
0.2 - 100

Personal
History
(n=87)

Family
History
(n=11)

Overall
(n=152)

0.6
0.1 - 3.9
0 - 88.6

0.9
0.4 - 9.1
0.2 - 32.6

3.85
0.3 - 47.8
0 - 100

Table 9 summarizes the calculated BRCAPro scores for males diagnosed with breast
cancer, pancreatic cancer, or prostate cancer who were seen due to their cancer diagnosis. It
is seen that the highest median BRCAPro score of 3.6 was obtained for males diagnosed
with breast cancer. The IQR for these males was 0.7 – 12.3 and a range from as low as 0 to
as high as 88.6. The lowest median BRCAPro score of 0.2 was obtained for males diagnosed
with pancreatic cancer with an IQR of 0 – 0.3 and a range from as low as 0 to as high as
20.2.

Table 9: BRCAPro Calculated Scores by Cancer Diagnosis
BRCAPro Number

Breast Cancer
(n= 44)

Median
IQR

3.6
0.7 – 12.3

Pancreatic
Cancer
(n= 16)
0.2
0 – 0.3

Range

0 – 88.6

0 – 20.2

Prostate
Cancer
(n= 35)
0.45
0.075 – 1.65
0 – 88.6
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ROC Curves
The overall maximum Youden’s J of 0.165 was obtained at a BRCAPro threshold of
32 at which sensitivity is equal to 75% and specificity is equal to 87%. Positive predictive
value (PPV) at a threshold of 32 is equal to 72% and negative predictive value (NPV) at this
threshold is equal to 88%. When the BRCAPro threshold is lowered to 12, sensitivity
increases to 77%, specificity decreases to 75%, PPV decreases to 59% and NPV remains the
same at 88%. The value for specificity and PPV decrease when the BRCAPro score is
lowered due to the fact that the number of false positives increases. This calculation
included the entire cohort of 152 individuals and is represented in figure 11.

Overall ROC Curve Including All Study Participants
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Figure 11: Overall ROC Curve Including All Study Participants
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For males with a KFM a maximum Youden’s J of 0.369 was obtained at a BRCAPro
threshold of 32 at which sensitivity is equal to 94% and specificity is equal to 42%. PPV at
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a threshold of 32 is equal to 75% and NPV at this threshold is equal to 80%. The ROC curve
for males seen for a KFM is seen in figure 12.

ROC Curve for Males with Known Familial Mutation
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Figure 12: ROC Curve for Males with a Known Familial Mutation undergoing
Predictive BRCA Testing
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For males with a personal history suggestive of a BRCA mutation the area under the
ROC curve (AUC) was calculated as .50. Therefore the discriminatory value of the
BRCAPro model for males with an indication of personal history suggestive of a BRCA
mutation, or males seen with a personal diagnosis of either breast, prostate, or pancreatic
cancer is no different than random chance. The ROC curve for males with this indication is
found in figure 13.
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Figure 13: ROC Curve for Males with a Personal History of a BRCA Associated
Cancer
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For males with a family history suggestive of a BRCA mutation a maximum
Youden’s J of 0.542 was obtained at a BRCAPro threshold of 2 at which sensitivity is equal
to 67% and specificity is equal to 88%. PPV at a threshold of 2 is equal to 67% and NPV at
this threshold is equal to 88%. This indication subgroup had a very small n, as only 11 males
for seen for this indication. The ROC curve constructed for this sub section of our cohort is
found in figure 14.
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Figure 14: ROC Curve for Males with a Family History Suggestive of a BRCA
Mutation
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For males diagnosed with breast cancer it was found that a BRCAPro threshold of
56.2 predicts the presence of a BRCA mutation perfectly, since the only two individuals who
tested positive were the only men with breast cancer and an indication of 2 who had a score
higher than 56.2. The ROC curve for males diagnosed with breast cancer is found in figure
15.
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Figure 15: ROC Curve for Males Diagnosed with Breast Cancer
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For males who were diagnosed with prostate cancer, a maximum Youden’s J of 0.44
was obtained at a BRCAPro threshold of 1.0 at which sensitivity is equal to 67% and
specificity is equal to 77%. PPV at a threshold of 1.0 is equal to 40% and NPV at this
threshold is equal to 91%. The ROC curve for males diagnosed with prostate cancer is seen
in figure 16.
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Figure 16: ROC Curve for Males Diagnosed with Prostate Cancer
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For males with pancreatic cancer a maximum Youden’s J of 0.46 was obtained at a
BRCAPro threshold of 0.3. The ROC curve for pancreatic cancer patients demonstrates that
the BRCAPro5.1 model does not seem to be predictive for this particular patient population
in identifying BRCA mutation carriers. The AUC calculated was 0.56 which demonstrates a
discriminating ability that is not much different than random chance. The ROC curve for
males diagnosed with pancreatic cancer is found in figure 17.
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Figure 17: ROC Curve for Males Diagnosed with Pancreatic Cancer
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A ranksum statistical test was run on the two variables of breast cancer development
and BMI. There was an association found due to a p value that was <0.00005. The median
BMI for males without breast cancer was 26.02 with an IQR of 24.57 to 28.40. The median
BMI for males diagnosed with breast cancer was 30.78 with an IQR of 27.42 to 33.43. The
box and whisker plot of this association is shown in figure 18.
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Figure 18: Box and Whisker Plot of Breast Cancer Development by BMI

An association was found between development of pancreatic cancer and BMI, as a
p-value of 0.0002 was obtained by running a ranksum test. The median BMI for males not
diagnosed with pancreatic cancer was 29.21 with an IQR of 26.04 to 32.08. The median
BMI for males diagnosed with pancreatic cancer was 25.95 with an IQR of 23.95 to 27.73.
The box and whisker plot of this association is shown in figure 21.
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Figure 19: Box and Whisker Plot of Pancreatic Cancer Development by BMI
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DISCUSSION
This is the first study that seeks to evaluate the accuracy of the BRCAPro5.1 risk
assessment model specifically in males. The aim of our study was to see how this particular
model performed overall in our cohort of males seen for numerous different clinical
indications for BRCA genetic testing. Additionally, other factors such as ethnicity, age of
diagnosis, presence of gynecomstatia, weight, height, etc., were obtained from the medial
records of our study population and also tested for significance.

BMI
Males who had a higher BMI had a statistically significant increased risk of breast
cancer (p<0.00005). According to the World Health Organization, BMI calculations can be
classified into four categories: underweight with a BMI <18.5, normal with a BMI between
18.5 to 24.9, overweight with a BMI of 25.0 to 29.9 and obese with a BMI over 30 [44].
Previous studies have shown that having a BMI ≥ 25.0 confers an increased risk for cancers
specifically: endometrial cancer in women, postmenopausal breast cancer in women, renal
cell carcinoma, colon cancer particularly in males and esophageal adenocarcinoma [45].
This finding is consistent with the current literature on increased BMI seen in males with
breast cancer. One study published in 2002 reported a trend seen in 43 male breast cancer
patients towards having a higher BMI, as the average BMI was reported to be 26.54 [46].
At this point in time the mechanisms for increased BMI in relation to male breast cancer are
not fully understood however, it is hypothesized that having an increased surface area of
breast tissue may predispose to the development of breast cancer in males. Another
hypothesis is that obesity lowers IGFBP 1 & 2 and thus increases the availability of IGF-1.

47

Increased bioavailability of IGF-1 along with insulin have been thought to increase cell
proliferation and decrease apoptosis, although this association has yet to be proven [47].
There is some debate as to which measure is most appropriate in order to investigate
associations between weight and cancer development, as some feel other measures such
waist-to-hip ratio (WHR) measurement may be more appropriate in order to access for body
fat distribution which is not accounted for with BMI. Other limitations previously noted
with BMI calculations is the fact that it performs with less accuracy in individuals >65 years
old as well as in Asian individuals [44]. BMI was chosen as the most appropriate calculation
for our study cohort, due to the fact that recorded heights and weights were able to be found
within the electronic medical record, other measurements such as WHR were not recorded.
Also very few males were noted to be of Asian ancestry within our study cohort.
In our cohort of males who developed pancreatic cancer, it was noted that their
median BMI was actually lower in comparison to males who did not develop pancreatic
cancer. The median BMI for males diagnosed with pancreatic cancer was 25.95 with an IQR
of 23.95 to 27.73. The median BMI for males without pancreatic cancer was 29.21 with an
IQR of 26.04 to 32.08. Previous studies have shown that there is an association between
increased BMI to have an increased risk for pancreatic cancer in both males and females
[45]. However, our cohort does not shown this same association, which may be explained by
several different factors. The height and weight measurements used to calculate BMI were
taken from the patient’s initial clinic visit, since a symptom of pancreatic cancer can be
severe weight loss it can be postulated that patients with pancreatic cancer may have been
under their typical weight at the time of their initial visit. Additionally, it was not noted
whether patients in our cohort had a history of cigarette or tobacco use, which have been
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found to be associated with the development of pancreatic cancer. Males who had a positive
history of tobacco use may have lower recorded weights due to the increase in metabolism
seen with tobacco use. Additionally as seen with male breast cancer and pancreatic cancer,
some studies suggest that being overweight or obese as defined by one’s BMI calculation is
a risk factor in the development of prostate cancer. In our study cohort no significant
difference was observed between the median BMI of males with prostate cancer compared
to the median BMI of males without prostate cancer.

BRCA Mutation Results
In our study cohort it was observed that more males were found to be BRCA2
positive (25) than BRCA1 (23) positive. There does not appear to be a significant difference
between these two groups. The same number of BRCA1 and BRCA2 mutations, 17, were
identified for males in our cohort who underwent testing for a KFM. Perhaps the finding of
slightly more BRCA2 mutation carriers can be attributed to the high number of males seen
within our cohort who were diagnosed with pancreatic cancer, as it is characterized in the
literature that BRCA2 mutation carriers confer a higher lifetime risk for pancreatic cancer in
comparison to BRCA1 carriers [5]. Overall in our cohort, 8 males were found to have
pancreatic cancer and a BRCA2 mutation while 1 male was found to have pancreatic cancer
and a BRCA1 mutation, therefore when we take these males diagnosed with pancreatic
cancer out, 21 males were found to be BRCA1 mutation carriers and 17 males were found to
be BRCA2 mutation carriers.
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BRCAPro5.1 Calculations
When looking at the median BRCAPro score calculated by indication, there was a
large difference in the median generated for males with a KFM in comparison to males with
an indication of either having a personal history of a BRCA related cancer diagnosis or for a
suggestive family history. For males with a KFM, the median BRCAPro score was 49.4,
which is expected as individuals undergoing predictive testing are commonly at a 50% risk
to have inherited the particular familial mutation based purely on autosomal dominant
inheritance and pedigree analysis. The BRCAPro risk assessment model can alter an
individual’s likelihood to test positive based on age of the individual at the time of testing
and personal history of cancer diagnoses. An example from our cohort that illustrates the
adjustment to a BRCAPro calculation based on age for males undergoing predictive testing
is seen with an unaffected male who underwent predictive testing at the age of 58 with a
BRCAPro score of 47.4 as compared to an unaffected male who had predictive testing at the
age of 20 who was found to have a BRCAPro score of 50%, both individuals tested positive
for their known familial mutations, which were both BRCA1 mutations.
When looking at the median BRCAPro scores for males with either a personal
history suggestive of a BRCA mutation or with an indication of a family history suggestive
of a BRCA mutation, they appear low with the median scores being 0.6 and 0.9, respectively.
The low scores may be explained by the fact that the only cancers calculated in the current
BRCAPro5.1 model are breast and ovarian cancers. Therefore, males who are themselves
diagnosed or who have family members who are diagnosed with other BRCA associated
cancers such as prostate or pancreatic cancers are counted as an unaffected individual by the
model. Although it is known that BRCA mutation carriers are at increased lifetime risks to
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develop both prostate cancer in males and pancreatic cancer, it may prove to be difficult in
assessing how these cancers best fit into the mathematical equation utilized in the BRCAPro
model.
A statistically significance difference was noted in regard to the calculated BRCAPro
scores across the three indications with a p-value of 0.0001. However no significant
difference was noted in regard to ethnicity or the presence of Ashkenazi Jewish ancestry in
regard to BRCAPro scores, which may be due to the small number of individuals in these
categories. Within our cohort it was found that age of diagnosis was not statically significant
(p = 0.68).

Overall Performance of the BRCAPro5.1 Model
When looking at the overall ROC curve constructed for the entire cohort the model
performed quite well at an AUC of 0.8070 since an AUC of 1.00 is representative of a
“perfect test” or one with a perfect discriminating ability in determining BRCA carriers from
non-carriers. At a BRCAPro threshold of 32, obtained through calculating the maximum
Youden’s J value, sensitivity of the BRCAPro model was equal to 75% and specificity was
equal to 87%. The positive predictive value at the threshold of 32 was 72% while the
negative predictive value was 88%. From these calculations it can be deduced that at our set
threshold, BRCAPro had a better ability to determine males who were negative for BRCA
mutations than positive.
The BRCAPro model can be used as not only a guide on how likely it is for a given
individual to be a BRCA mutation carrier, but also under certain circumstances may in fact
serve as a substitute for testing [41]. Thus when deciding at what level to set our threshold
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for BRCAPro scores to calculate our ROC curves, it was decided to determine the optimal
threshold by utilizing the maximum Youden’s J calculation, since equal importance was
placed on sensitivity and specificity. In the case of substituting BRCAPro scores for actual
BRCA testing it can be argued that harm may be inflicted by calling either false negatives or
false positives. It is a matter of opinion as to which of these outcomes is worse. Calling false
negatives inaccurately assures individuals that they are not at an increased risk to develop
BRCA associated cancers. If these individuals are not actively being screened for their
increased cancer risks then there is potential for the development and advancement of
cancers. The psychosocial impacts of calling false negatives must also be factored in when
discussing potential harm caused to these individuals. On the converse side, calling false
positives may also create certain unwarranted psychosocial harm. Additionally, false
positives may inflict harm by means of an increased proportion of health care dollars being
spent to ensure increased screening for these individuals who in actuality are not at
increased risk.

ROC Curves Subdivided by Indication
The ROC curve constructed for males seen with a KFM had it’s maximum Youden’s
J at a BRCAPro threshold of 32, at which sensitivity is equal to 94% and specificity is equal
to 42%. The AUC was calculated to be 0.68, which corresponds to a relatively poor
discriminating ability, similarly the AUC calculated for males with a personal history
suggestive of a BRCA mutation was found to be 0.50, which is the same discriminating
ability as random chance. This finding may be explained by the fact that neither prostate or
pancreatic cancers can be accounted for in the BRCAPro model, which could thus
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significantly lower the BRCAPro calculations for males with personal histories of these
cancers and/or family histories of these particular cancers.
The least common indication to seek genetic counseling in our cohort was that of
having a family history suggestive of a BRCA mutation, as only 11 males were seen for this
indication. The AUC calculated by the ROC curve was 0.77, and therefore there was a
decent discriminating ability with the BRCAPro model for males with this indication. Thus,
BRCAPro may be helpful for men with family histories of breast and/or ovarian cancer
while not helpful for men with family histories abundant in prostate or pancreatic cancer
diagnoses.

ROC Curves Subdivided by Cancer Development and Type
There were seven male probands included in the initial study that validated the use of
the BRCAPro model in the clinical setting only three of which had male breast cancer [41].
All three were found to be BRCA2 mutation carriers which may have skewed the results
with the BRCAPro scores calculated for these three males all being found to be greater than
95. Which is similar to our finding that BRCAPro had a perfect discriminating ability in
males with breast cancer at a BRCAPro calculation above 56.2 [41].
One previously published paper aimed to evaluate the use of the BRCAPro5.0 model
in 102 Italian male breast cancer patients, and found at a set threshold of 10% the model had
a sensitivity of 0.80, specificity of 0.78, positive predictive value of 0.29 and a negative
predictive value of 0.97 [34]. This particular study utilized this threshold as this is the
threshold value that the FHAT model uses [34]. Our study threshold used for our male
breast cancer patients was obtained by calculating the Youden’s J value. However when we
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set our BRCAPro threshold to 10% we obtained a sensitivity of 100%, specificity of 76%,
positive predictive value of 16% and negative predictive value of 100%. Therefore our
findings were quite similar to those produced by the previous study conducted by Zanna et
al, as both studies found the BRCAPro model to have higher sensitivity than specificity and
very high negative predictive values with low positive predictive values.
The ROC curve constructed for males who were diagnosed with prostate cancer gave
a calculated AUC of 0.69. The ROC curve constructed for males with pancreatic cancer seen
for genetic counseling due to their personal cancer diagnosis had a AUC of 0.56. Again this
finding may be due to the fact that males with a prostate cancer diagnosis are treated as
unaffected individuals. In many cases prostate cancer may be a sporadic cancer due to
advancing age, however early onset prostate cancer may in fact be more suggestive of a
BRCA mutation. However, the current BRCAPro model has no way to account for such
differences.

Study Limitations
This research project was a retrospective chart review, and there are several
limitations noted. First and foremost, the overall study size is rather small with a total
cohort of 152 males. Additionally all males in this study were patients at the same hospital
and therefore the results may not translate to all other male patient populations seeking
BRCA testing since demographic information may be different at different cancer centers.
Due to the nature of a retrospective chart review, some information was missing
from the medical records for our study participants. For instance, height and weight of study
participants were ascertained from the patient history database which is information taken
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during their first clinical visit by a nurse. Many study participants were missing this
information as 77 males were missing a recorded height and 74 males were missing a
recorded weight. Other variables such as gynecomastia were researched in this study;
however, it was only noted as being present if documented in the medical record. Therefore,
there could have been more male patients with gynecomastia who were not denoted to have
this condition if it was left out of their dictated medical notes.
An additional limitation of our study is the fact that family history is patient reported,
which could potentially lead to misrepresentation of the family history as cancer diagnoses
may be underestimated, overestimated, and/or simply incorrect. Study participants with a
personal diagnosis of cancer were able to be verified through pathology reports from MD
Anderson, although patients that present for a second opinion to MD Anderson may have
pathology reports from an outside hospital or no pathology report present in their medical
record.
One last limitation of this study can be attributed to the way clinical BRCA testing is
currently conducted in the United States through Myriad Genetics Laboratories. The most
comprehensive of testing to date includes both comprehensive sequencing as well as
reflexing when a negative comprehensive test result is received to a large arrangement test
that uses MLPA analysis known as BART®. In our study cohort only 14 (9.21%) males
underwent BART® testing. Therefore the majority of our cohort did not receive the absolute
most comprehensive testing available as of 2012. There are numerous reasons a study
participant may not have BART® performed, whether it was that they were tested before
August 2006 when the test first became clinically available or they did not wish to incur the
additiona cost of the test. For study participants who tested negative through either single
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site analysis or multisite analysis, they would then need to reflex to comprehensive
sequencing and then additionally BART® testing in the event the comprehensive
sequencing was negative to be considered to have the most comprehensive testing to date.
However, the residual risk to have a BRCA mutation after having either negative single site
or negative multisite testing is very small and therefore many patients do not wish to
continue further BRCA testing, especially with the relatively high cost of testing.

Implications and Future Research
Currently figures quoted in the medical literature provides a wide range of the
likelihood a case of male breast cancer is attributable to a BRCA mutation from 4% to 40%.
Although the overall sample size of males who had breast cancer without having a KFM is
rather small in our cohort at 46, only 2 of these males had a BRCA mutation more
specifically a BRCA2 mutation, which is a significantly lower number than expected.
Clearly more research and attention needs to be placed on determining what factors are
causing male breast cancer, as the literature appears to overestimate the contribution that
BRCA mutations have in regard to male breast cancer. There may in fact be specific genetic
factors aside from BRCA mutations that play a role in the development of male breast
cancer; therefore, research is needed to identify what these genetic factors are.

Conclusion
In conclusion, our study was able to find the ideal BRCAPro score threshold for both
clinical indications and cancer subtype within our cohort. When lowering the BRCAPro
score closer to the study populations overall median BRCAPro score (3.85) it was
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demonstrated that the model performs inadequately. For males with an indication of having
a personal cancer history, BRCAPro5.1 performed the same as random chance. Our study
discovered that the BRCAPro5.1 model had perfect discriminating ability for males with
breast cancer at a threshold of 56.2, as all of our male breast cancer patients with a BRCA
mutation had a BRCAPro score well above this threshold. However, it is important to note
that our sample size of male breast cancer patients was small, and this finding should not be
applied to other male breast cancer cohorts. Additionally, adjusting the threshold to 10
demonstrates that BRCAPro is overestimating the likelihood that a man with breast cancer
would test positive. The discriminating ability of the model for males with a personal or
family history of pancreatic or prostate cancer was very poor. Directions for the future
should include a large multicenter study combining patients diagnosed with male breast
cancer to increase the overall sample size and further evaluate the validity of the findings
from our study. Lastly, consideration should be given to determine a way to account for
prostate and pancreatic cancers in future versions of the BRCAPro risk assessment model,
which in turn might better evaluate the risk for males to test positive for BRCA mutations.
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